��Lower stock prices. The steely professionals on Wall Street know that a crisis always produces bargains in stocks, which is why they nearly always panic and sell at the first sign of trouble. Fortunately, they later regain their calm and buy the stocks they sold, typically a few days later. The Standard and Poor's 500 stock index fell 0.56% in early Monday trading.
��Higher energy prices, particularly in Europe. Brent crude oil gained nearly 2.2% in early European trading Monday, while natural gas futures surged more than 10% in the U.K., according to Bloomberg. Russia is one of Europe's main energy suppliers.
Top 10 Sliver Stocks To Buy Right Now: Flamel Technologies S.A.(FLML)
Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer based technology in the United Kingdom, Ireland, the United States, France, and Europe. The company develops nanogel Medusa technology, which is intended to provide controlled release following injection of therapeutic proteins, peptides, and other molecules; a microparticle adaptation of the Medusa platform that is intended for use in the delivery of smaller proteins and peptides; and Micropump technology, a microparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement; and Trigger-Lock technology, an adaptation based on Micropump technology, which is intended to minimize the misuse and abuse of medications subject to abuse. Its principal product based on Micropump technology is Coreg CR, which is intended for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. The company?s products under development based upon Medusa technology include Interferon-alpha, a naturally occurring protein that the body uses for the treatment of Hepatitis C virus and as a immune response; and FT-105, an injectable insulin formulation for diabetic patients. Its products based on its Micropump technology comprise LiquiTime for the elderly and pediatric patient patients, or others who have difficulty swallowing. The company has strategic alliance with Baxter International, Inc.; GlaxoSmithKline; Merck Serono; and Pfizer Inc, as well as has a joint development agreement with Digna Biotech, S.L. Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France.
Advisors' Opinion:- [By Garrett Cook]
Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).
- [By Garrett Cook]
Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).
- [By Anna Prior]
Flamel Technologies SA(FLML) said the U.S. Food and Drug Administration has approved the company’s new drug application for Vazculep, an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. American depositary shares rose 5.1% to $14.78 in premarket trading.
Hot European Companies To Invest In 2014: TotalFinaElf S.A.(TOT)
TOTAL S.A., together with its subsidiaries, operates as an integrated oil and gas company worldwide. The company operates through three segments: Upstream, Downstream, and Chemicals. The Upstream segment engages in the exploration, development, and production of oil and natural gas. It also involves in the transportation, trade, and marketing of natural gas and liquefied natural gas (LNG), as well as in LNG re-gasification and natural gas storage operations. In addition, this segment engages in the shipping and trade of liquefied petroleum gas (LPG); power generation from gas-fired power plants, nuclear, or renewable energies; production, trade, and marketing of coal, as well as in solar power systems and technology operations. As of December 31, 2010, it had combined proved reserves of 10,695 Mboe of oil and gas. The Downstream segment involves in refining, marketing, trading, and shipping crude oil and petroleum products. It also produces a range of specialty products, s uch as lubricants, LPG, jet fuel, special fluids, bitumen, marine fuels, and petrochemical feedstock. This segment holds interests in 24 refineries located in Europe, the United States, the French West Indies, Africa, and China, as well as operates a network of 17,490 service stations. The Chemicals segment produces base chemicals, including petrochemicals and fertilizers, as well as engages in rubber processing, resins, adhesives, and electroplating activities. TOTAL S.A. was founded in 1924 and is based in Paris, France.
Advisors' Opinion:- [By Arjun Sreekumar]
For instance, Total SA (NYSE: TOT ) recently threw in the towel on its Voyageur�Upgrader project, a 200,000-barrels-a-day facility that was designed to "upgrade" bitumen into crude oil. It sold its 49% stake in Voyageur to its joint venture partner, Suncor Energy (NYSE: SU ) , for $500 million, arguing that the project was "no longer justified from a strategic and economic" standpoint. Not long after, Suncor also decided to abandon the project, for which it took a C$1.5 billion write-down.
- [By Robert Rapier]
On Dec. 5, IOC issued an extensive press release trumpeting the sale to Total (NYSE: TOT) of an interest in its Papua New Guinea exploration. The IOC press release spun the sale as potentially worth billions to IOC, which has a current market cap of $2.6 billion. Indeed, that deal sounds like it could really make a huge impact on IOC, until you read the press release issued by Total. Total has indicated that its engineers will need to evaluate the prospects before any decision is made on payments. So the deal could be worth zero to IOC, and based on the company’s poor track record over the years in actually booking reserves many investors decided it was time to exit when it became clear that IOC’s spin on the deal was much different than Total’s. Shares fell 21 percent in pre-market trading on the day of the announcement, and are now down about 40 percent since the Total news hit.
Hot European Companies To Invest In 2014: British American Tobacco Industries p.l.c.(BTI)
British American Tobacco p.l.c., through its subsidiaries, engages in the manufacture, distribution, and sale of tobacco products. The company offers cigars, cigarettes, smokeless snus, roll-your-own, and pipe tobacco products under the Dunhill, Kent, Lucky Strike, Pall Mall, Vogue, Viceroy, Kool, Rothmans, Peter Stuyvesant, Benson & Hedges, and State Express 555 brand names. It has operations in the Asia-Pacific, the Americas, eastern and western Europe, Africa, and the Middle East. The company was founded in 1902 and is headquartered in London, the United Kingdom. British American Tobacco p.l.c. operates independently of Remgro Ltd. as of November 03, 2008.
Advisors' Opinion:- [By Jon Wallis]
LONDON -- British American Tobacco� (LSE: BATS ) (NYSE: BTI) -- the world's second-biggest cigarette maker -- is currently up more than 2% following this morning's interim management statement for the first quarter of 2013, in which the company reported revenue growth of 5% (on a constant current basis) despite difficult market conditions.
- [By G. A. Chester]
British American Tobacco (LSE: BATS ) (NYSEMKT: BTI ) , Tesco (LSE: TSCO ) (NASDAQOTH: TSCDY ) , and Severn Trent (LSE: SVT ) fit the bill, and the table below gives the low-down on them.
- [By Roland Head]
LONDON -- Tobacco giants�British American Tobacco� (LSE: BATS ) (NYSEMKT: BTI ) and�Imperial Tobacco Group� (LSE: IMT ) (NASDAQOTH: ITYBY ) sell more than 1 trillion cigarettes every year.
- [By Peter Stephens]
The tide, it seems, is turning against tobacco companies such as�British American Tobacco� (LSE: BATS ) (NYSEMKT: BTI ) .
Hot European Companies To Invest In 2014: Fresenius Medical Care Corporation (FMS)
Fresenius Medical Care AG & Co. KGaA, a dialysis company, provides products and services for patients with chronic kidney diseases. As of May 12, 2011, it provided dialysis care services to 216,942 patients through its network of 2,769 dialysis clinics primarily in North America, Europe, Latin America, the Asia-Pacific, and Africa. The company also develops and manufactures various dialysis products, including hemodialysis machines, dialyzers, hemofilters, dialysis fluid filters, tubing systems, fistula needles, dialysis related equipment, acute hemodialysis machines, plasma filters, acute tubing systems and cassettes, catheters, and related disposable products for chronic hemodialysis, acute therapy, home therapy, and therapeutic apheresis, as well as dialysis drugs. In addition, it provides laboratory services. Fresenius Medical sells its products through distributors. The company was founded in 1996 and is headquartered in Bad Homburg, Germany.
Advisors' Opinion:- [By Johanna Bennett]
The Centers for Medicare and Medicaid decided today to cut government payment to dialysis clinics. So why did share prices for DaVita HealthCare Partners (DVA) and rival Fresenius Medical Care (FMS) rise so steeply today?
- [By John Udovich]
Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with�the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA)�and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).�
- [By Louie Grint]
Still unaffected
First, Fresenius Medical Care (NYSE: FMS ) is the No. 1 global provider of dialysis equipment. It enjoys leading market share of almost 33% in its home country. - [By Johanna Bennett]
Dialysis provider DaVita Healthcare Partners (DVA) soared almost 8.9% to close at $61.55 after the market learned that Medicare funding cuts would come in lower than expected. Rival Fresenius Medical Care (FMS) rose 7.2% on the same news.
No comments:
Post a Comment